{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,25]],"date-time":"2026-09-25T14:44:50Z","timestamp":1790347490519,"version":"4.1.0"},"reference-count":42,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2022,10,1]],"date-time":"2022-10-01T00:00:00Z","timestamp":1664582400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinical-genitourinary-cancer.com","clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinical Genitourinary Cancer"],"published-print":{"date-parts":[[2022,10]]},"DOI":"10.1016\/j.clgc.2022.04.008","type":"journal-article","created":{"date-parts":[[2022,4,25]],"date-time":"2022-04-25T04:29:11Z","timestamp":1650860951000},"page":"391-398","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"title":["A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)"],"prefix":"10.1016","volume":"20","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-6621-8251","authenticated-orcid":false,"given":"Fernando Sabino M.","family":"Monteiro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrey","family":"Soares","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vinicius Carrera","family":"Souza","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rubens Copia","family":"Sperandio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Enrique","family":"Grande","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Santoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Poisl","family":"Fay","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andre Deeke","family":"Sasse","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.clgc.2022.04.008_bib0001","first-page":"666","article-title":"Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients","volume":"19","author":"Stein","year":"2001","journal-title":"J Clin Oncol"},{"issue":"1","key":"10.1016\/j.clgc.2022.04.008_bib0002","first-page":"62","article-title":"Chemotherapy for bladder cancer: treatment guidelines for neoadjuvant chemotherapy, bladder preservation, adjuvant chemotherapy, and metastatic cancer","volume":"69","author":"Sternberg","year":"2007","journal-title":"Urology"},{"key":"10.1016\/j.clgc.2022.04.008_bib0003","first-page":"497","article-title":"Discerning patterns and quality of neoadjuvant chemotherapy use among patients with muscle-invasive bladder cancer","volume":"2","author":"Huo","year":"2019","journal-title":"Eur Urol Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0004","first-page":"803","article-title":"Factors associated with utilization of neoadjuvant chemotherapy in charlson comorbidity zero non-metastatic muscle-invasive bladder cancer patients","volume":"47","author":"Au","year":"2021","journal-title":"Int Braz J Urol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0005","first-page":"154","article-title":"Social and clinical correlates of neoadjuvant chemotherapy in medicare beneficiaries with muscle invasive bladder cancer from 2004-2015","volume":"149","author":"Nyame","year":"2021","journal-title":"Urology"},{"issue":"18_suppl","key":"10.1016\/j.clgc.2022.04.008_bib0006","article-title":"Randomized phase III trial comparing adjuvant paclitaxel\/gemcitabine\/cisplatin (PGC) to observation in patients with resected invasive bladder cancer: results of the Spanish Oncology Genitourinary Group (SOGUG) 99\/01 study","volume":"28","author":"Paz-Ares","year":"2010","journal-title":"Journal of Clinical Oncology"},{"key":"10.1016\/j.clgc.2022.04.008_bib0007","first-page":"695","article-title":"Adjuvant chemotherapy with cisplatin and gemcitabine versus chemotherapy at relapse in patients with muscle-invasive bladder cancer submitted to radical cystectomy: an Italian, multicenter, randomized phase III trial","volume":"23","author":"Cognetti","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0008","first-page":"76","article-title":"Immediate versus deferred chemotherapy after radical cystectomy in patients with pT3-pT4 or N+ M0 urothelial carcinoma of the bladder (EORTC 30994): an intergroup, open-label, randomised phase 3 trial","volume":"16","author":"Sternberg","year":"2015","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0009","first-page":"1218","article-title":"Avelumab maintenance therapy for advanced or metastatic urothelial carcinoma","volume":"383","author":"Powles","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.clgc.2022.04.008_bib0010","first-page":"970","article-title":"Randomized phase III KEYNOTE-045 trial of pembrolizumab versus paclitaxel, docetaxel, or vinflunine in recurrent advanced urothelial cancer: results of >2 years of follow-up","volume":"30","author":"Fradet","year":"2019","journal-title":"Ann Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0011","first-page":"439","article-title":"Updated results of pure-01 with preliminary activity of neoadjuvant pembrolizumab in patients with muscle-invasive bladder carcinoma with variant histologies","volume":"77","author":"Necchi","year":"2020","journal-title":"Eur Urol"},{"issue":"15_suppl","key":"10.1016\/j.clgc.2022.04.008_bib0012","first-page":"5047","article-title":"Phase Ib\/II neoadjuvant (N-) pembrolizumab (P) and chemotherapy for locally advanced urothelial cancer (laUC): final results from the cisplatin (C)- eligible cohort of HCRN GU14-188","volume":"38","author":"Hoimes","year":"2020","journal-title":"J Clin Oncol"},{"issue":"6_suppl","key":"10.1016\/j.clgc.2022.04.008_bib0013","first-page":"439","article-title":"Results from BLASST-1 (Bladder Cancer Signal Seeking Trial) of nivolumab, gemcitabine, and cisplatin in muscle invasive bladder cancer (MIBC) undergoing cystectomy","volume":"38","author":"Gupta","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0014","first-page":"1839","article-title":"Preoperative ipilimumab plus nivolumab in locoregionally advanced urothelial cancer: the NABUCCO trial","volume":"26","author":"van Dijk","year":"2020","journal-title":"Nat Med"},{"key":"10.1016\/j.clgc.2022.04.008_bib0015","first-page":"525","article-title":"Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial","volume":"22","author":"Bellmunt","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0016","first-page":"2102","article-title":"Adjuvant nivolumab versus placebo in muscle-invasive urothelial carcinoma","volume":"384","author":"Bajorin","year":"2021","journal-title":"New England J Med"},{"key":"10.1016\/j.clgc.2022.04.008_bib0017","first-page":"n71","article-title":"The PRISMA 2020 statement: an updated guideline for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.clgc.2022.04.008_bib0018","first-page":"79","article-title":"The evolution of assessing bias in Cochrane systematic reviews of interventions: celebrating methodological contributions of the Cochrane Collaboration","volume":"2","author":"Turner","year":"2013","journal-title":"Systemat Rev"},{"key":"10.1016\/j.clgc.2022.04.008_bib0019","first-page":"1223","article-title":"Placebo effect studies are susceptible to response bias and to other types of biases","volume":"64","author":"Hr\u00f3bjartsson","year":"2011","journal-title":"J Clin Epidemiol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0020","first-page":"367","article-title":"Comparison of four PD-L1 immunohistochemical assays in lung cancer","volume":"13","author":"Hendry","year":"2018","journal-title":"J Thoracic Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0021","first-page":"99","article-title":"Concordance among four commercially available, validated programmed cell death ligand-1 assays in urothelial carcinoma","volume":"14","author":"Zajac","year":"2019","journal-title":"Diagnostic Pathol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0022","first-page":"1547","article-title":"Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial","volume":"395","author":"Galsky","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.clgc.2022.04.008_bib0023","first-page":"1574","article-title":"Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial","volume":"21","author":"Powles","year":"2020","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0024","first-page":"931","article-title":"Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial","volume":"22","author":"Powles","year":"2021","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0025","article-title":"Chemotherapy is superior to checkpoint inhibitors after radical surgery for urothelial carcinoma: a systematic review and network meta-analysis of oncologic and toxicity outcomes","volume":"169","author":"Laukhtina","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0026","first-page":"420","article-title":"A consensus molecular classification of muscle-invasive bladder cancer","volume":"77","author":"Kamoun","year":"2020","journal-title":"Eur Urol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0027","first-page":"312","article-title":"Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial","volume":"18","author":"Sharma","year":"2017","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0028","first-page":"48","article-title":"Molecular intricacies of upper tract urothelial carcinoma and their relevance for therapy considerations","volume":"32","author":"Berndl","year":"2022","journal-title":"Curr Opin Urol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0029","first-page":"2977","article-title":"Upper tract urothelial carcinoma has a luminal-papillary T-cell depleted contexture and activated FGFR3 signaling","volume":"10","author":"Robinson","year":"2019","journal-title":"Nat Commun"},{"key":"10.1016\/j.clgc.2022.04.008_bib0030","first-page":"e1395","article-title":"Comparison of genomic characterization in upper tract urothelial carcinoma and urothelial carcinoma of the bladder","volume":"26","author":"Yang","year":"2021","journal-title":"Oncologist"},{"key":"10.1016\/j.clgc.2022.04.008_bib0031","first-page":"196","article-title":"Immune checkpoint inhibitors in advanced upper and lower tract urothelial carcinoma: a comparison of outcomes","volume":"128","author":"Esagian","year":"2021","journal-title":"BJU Int"},{"issue":"17","key":"10.1016\/j.clgc.2022.04.008_bib0032","first-page":"4341","article-title":"Efficacy of immune checkpoint inhibitors in upper tract urothelial carcinomas: current knowledge and future directions","volume":"13","author":"Thouvenin","year":"2021","journal-title":"Cancers (Basel)"},{"key":"10.1016\/j.clgc.2022.04.008_bib0033","article-title":"Outcome of patients with advanced upper tract urothelial carcinoma treated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"159","author":"Bersanelli","year":"2021","journal-title":"Crit Rev Oncol Hematol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0034","first-page":"35","article-title":"Clinical relevance and prognostic significance of PD-1\/PD-Ls in non-metastatic bladder cancer: a role for PD-L2","volume":"124","author":"Ariafar","year":"2020","journal-title":"Mol Immunol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0035","first-page":"261","article-title":"PD-L2 is a second ligand for PD-1 and inhibits T cell activation","volume":"2","author":"Latchman","year":"2001","journal-title":"Nat Immunol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0036","article-title":"PD-L2 amplification and durable disease stabilization in patient with urothelial carcinoma receiving pembrolizumab","volume":"7","author":"George","year":"2018","journal-title":"Oncoimmunology"},{"key":"10.1016\/j.clgc.2022.04.008_bib0037","first-page":"1088","article-title":"Looking for the optimal PD-1\/PD-L1 inhibitor in cancer treatment: a comparison in basic structure, function, and clinical practice","volume":"11","author":"Chen","year":"2020","journal-title":"Front Immunol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0038","first-page":"375","article-title":"Use of immunotherapy with programmed cell death 1 vs programmed cell death ligand 1 inhibitors in patients with cancer: a systematic review and meta-analysis","volume":"6","author":"Duan","year":"2020","journal-title":"JAMA Oncol"},{"key":"10.1016\/j.clgc.2022.04.008_bib0039","first-page":"201","article-title":"Inhibitory functions of PD-L1 and PD-L2 in the regulation of anti-tumor immunity in murine tumor microenvironment","volume":"68","author":"Umezu","year":"2019","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.clgc.2022.04.008_bib0040","first-page":"432","article-title":"ctDNA guiding adjuvant immunotherapy in urothelial carcinoma","volume":"595","author":"Powles","year":"2021","journal-title":"Nature"},{"key":"10.1016\/j.clgc.2022.04.008_bib0041","unstructured":"A study of atezolizumab versus placebo as adjuvant therapy in patients with high-risk muscle-invasive bladder cancer who Are ctDNA positive following cystectomy (IMvigor011). [December 20, 2021 ]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT04660344."},{"key":"10.1016\/j.clgc.2022.04.008_bib0042","unstructured":"Testing MK-3475 (Pembrolizumab) after surgery for localized muscle-invasive bladder cancer and locally advanced urothelial cancer (AMBASSADOR) [December 15, 2021 ]. Available from: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT03244384."}],"container-title":["Clinical Genitourinary Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000854?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1558767322000854?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T11:36:52Z","timestamp":1761565012000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1558767322000854"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10]]},"references-count":42,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2022,10]]}},"alternative-id":["S1558767322000854"],"URL":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.008","relation":{},"ISSN":["1558-7673"],"issn-type":[{"value":"1558-7673","type":"print"}],"subject":[],"published":{"date-parts":[[2022,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Systematic Review and Meta-Analysis of the Role of Immune Checkpoint Inhibitors (ICI) as Adjuvant Treatment for Localized High-Risk Muscle-Invasive Urothelial Carcinoma (MIUC)","name":"articletitle","label":"Article Title"},{"value":"Clinical Genitourinary Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.clgc.2022.04.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}